Suvretta Capital Management LLC Raises Holdings in Fulcrum Therapeutics, Inc. $FULC

Suvretta Capital Management LLC boosted its holdings in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) by 5.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,381,000 shares of the company’s stock after acquiring an additional 298,100 shares during the quarter. Suvretta Capital Management LLC owned about 9.94% of Fulcrum Therapeutics worth $49,505,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Strs Ohio grew its holdings in shares of Fulcrum Therapeutics by 3.7% during the 3rd quarter. Strs Ohio now owns 77,900 shares of the company’s stock worth $717,000 after purchasing an additional 2,800 shares during the period. Farther Finance Advisors LLC raised its holdings in Fulcrum Therapeutics by 108.3% in the 3rd quarter. Farther Finance Advisors LLC now owns 7,112 shares of the company’s stock valued at $65,000 after buying an additional 3,697 shares during the period. Russell Investments Group Ltd. raised its holdings in Fulcrum Therapeutics by 47.5% in the 3rd quarter. Russell Investments Group Ltd. now owns 13,731 shares of the company’s stock valued at $126,000 after buying an additional 4,423 shares during the period. BNP Paribas Financial Markets lifted its position in Fulcrum Therapeutics by 137.9% in the third quarter. BNP Paribas Financial Markets now owns 14,274 shares of the company’s stock valued at $131,000 after buying an additional 8,275 shares during the last quarter. Finally, American Century Companies Inc. lifted its position in Fulcrum Therapeutics by 7.0% in the second quarter. American Century Companies Inc. now owns 132,349 shares of the company’s stock valued at $911,000 after buying an additional 8,638 shares during the last quarter. Hedge funds and other institutional investors own 89.83% of the company’s stock.

Fulcrum Therapeutics Stock Performance

NASDAQ FULC opened at $7.65 on Friday. The firm has a market cap of $509.49 million, a price-to-earnings ratio of -6.48 and a beta of 3.23. The firm has a 50 day simple moving average of $9.83 and a 200-day simple moving average of $9.58. Fulcrum Therapeutics, Inc. has a one year low of $2.32 and a one year high of $15.74.

Fulcrum Therapeutics (NASDAQ:FULC) last announced its earnings results on Tuesday, February 24th. The company reported ($0.31) earnings per share for the quarter, hitting the consensus estimate of ($0.31). Equities analysts predict that Fulcrum Therapeutics, Inc. will post -0.16 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on FULC shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research report on Thursday, January 22nd. Truist Financial set a $17.00 price objective on shares of Fulcrum Therapeutics in a research report on Tuesday, February 24th. The Goldman Sachs Group reiterated a “positive” rating on shares of Fulcrum Therapeutics in a report on Monday, December 8th. Royal Bank Of Canada upped their price target on Fulcrum Therapeutics from $7.00 to $10.00 and gave the stock a “sector perform” rating in a research note on Monday, December 8th. Finally, Leerink Partners reaffirmed an “outperform” rating on shares of Fulcrum Therapeutics in a research note on Tuesday, February 24th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Fulcrum Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $19.00.

Insider Buying and Selling at Fulcrum Therapeutics

In other news, Director Robert J. Gould sold 15,000 shares of the stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $11.87, for a total value of $178,050.00. Following the sale, the director directly owned 469,864 shares in the company, valued at approximately $5,577,285.68. This trade represents a 3.09% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 7.00% of the company’s stock.

Fulcrum Therapeutics Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.